US 12,357,699 B2
B-cell immunotherapy in cancer treatment
Shiladitya Sengupta, Waltham, MA (US); and Aniruddha Sengupta, Delhi (IN)
Assigned to Alyssum Therapeutic s, Inc., Cambridge, MA (US)
Appl. No. 17/258,610
Filed by AKAMARA THERAPEUTICS, INC., Philadelphia, PA (US)
PCT Filed Jul. 10, 2019, PCT No. PCT/US2019/041237
§ 371(c)(1), (2) Date Jan. 7, 2021,
PCT Pub. No. WO2020/014387, PCT Pub. Date Jan. 16, 2020.
Claims priority of provisional application 62/695,946, filed on Jul. 10, 2018.
Prior Publication US 2021/0275677 A1, Sep. 9, 2021
Int. Cl. A61K 47/55 (2017.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 47/551 (2017.08) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/554 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/585 (2013.01)] 14 Claims
 
1. A method of treating non-small cell lung cancer (NSCLC) in a subject in need thereof, comprising administering to the subject, compound IO-125:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody.